Matrix metalloproteinase inhibitor properties of tetracyclines: Therapeutic potential in cardiovascular diseases

Pharmacological Research

Volumn 64, Issue 6, 2011, Pages 551-560

  Castro, Michele M ^a   Kandasamy, Arulmozhi D ^a   Youssef, Nermeen ^a   Schulz, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Doxycycline; Inflammatory heart disease; Ischemia reperfusion injury; Matrix metalloproteinase; Septic shock; Tetracyclines

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; BATIMASTAT; DOXYCYCLINE; DOXYCYCLINE HYCLATE; GELATINASE A; GELATINASE B; ILOMASTAT; INCYCLINIDE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE; PD 166793; PG 116800; PLACEBO; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CHAGAS DISEASE; CORONARY ARTERY DISEASE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; HEART DEVELOPMENT; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; LUNG INJURY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK; VASCULARIZATION; VIRUS MYOCARDITIS;

ANIMALS; ANTI-BACTERIAL AGENTS; CARDIOVASCULAR DISEASES; HEART; HUMANS; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS; SEPSIS; TETRACYCLINES;

EID: 80054113262     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.05.005     Document Type: Review

References (165)

1. J. Gross, and C.M. Lapiere Collagenolytic activity in amphibian tissues: a tissue culture assay Proc Natl Acad Sci USA 48 1962 1014 1022
2. R. Roy, B. Zhang, and M.A. Moses Making the cut: Protease-mediated regulation of angiogenesis Exp Cell Res 312 2006 608 622 (Pubitemid 43290337)
3. T.H. Vu, and Z. Werb Matrix metalloproteinases: effectors of development and normal physiology Genes Dev 14 2000 2123 2133
4. F.F. Mohammed, D.S. Smookler, and R. Khokha Metalloproteinases, inflammation, and rheumatoid arthritis Ann Rheum Dis 62 2003 II43 II47
5. E.I. Deryugina, and J.P. Quigley Matrix metalloproteinases and tumor metastasis Cancer Metast Rev 25 2006 9 34 (Pubitemid 43723979)
6. M. Thompson, and G. Cockerill Matrix metalloproteinase-2: the forgotten enzyme in aneurysm pathogenesis Ann N Y Acad Sci 2006 170 174 (Pubitemid 47092005)
7. R. Visse, and H. Nagase Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry Circ Res 92 2003 827 839 (Pubitemid 36542523)
8. Z.S. Galis, and J.J. Khatri Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly Circ Res 90 2002 251 262 (Pubitemid 34633925)
9. M.M. Castro, E. Rizzi, L. Figueiredo-Lopes, K. Fernandes, L.M. Bendhack, and D.L. Pitol Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats Atherosclerosis 198 2008 320 331 (Pubitemid 351707391)
10. E.E. Creemers, J.P. Cleutjens, J.F. Smits, and M.J. Daemen Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89 2001 201 210 (Pubitemid 34132679)
11. C.M. Dollery, J.R. McEwan, and A.M. Henney Matrix metalloproteinases and cardiovascular disease Circ Res 77 1995 863 868
12. F.G. Spinale, M.L. Coker, B.R. Bond, and J.L. Zellner Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target Cardiovasc Res 46 2000 225 238 (Pubitemid 30204594)
13. P.Y. Cheung, G. Sawicki, M. Wozniak, W. Wang, M.W. Radomski, and R. Schulz Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart Circulation 101 2000 1833 1839 (Pubitemid 30213106)
14. R. Schulz Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches Annu Rev Pharmacol Toxicol 47 2007 211 242
15. W. Wang, C.J. Schulze, W.L. Suarez-Pinzon, J.R. Dyck, G. Sawicki, and R. Schulz Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury Circulation 106 2002 1543 1549
16. C.Q. Gao, G. Sawicki, W.L. Suarez-Pinzon, T. Csont, M. Wozniak, and P. Ferdinandy Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction Cardiovasc Res 57 2003 426 433 (Pubitemid 36144221)
17. G. Sawicki, H. Leon, J. Sawicka, M. Sariahmetoglu, C.J. Schulze, and P.G. Scott Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2 Circulation 112 2005 544 552 (Pubitemid 41060795)
18. M.M. Sung, C.G. Schulz, W. Wang, G. Sawicki, N.L. Bautista-Lopez, and R. Schulz Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury J Mol Cell Cardiol 43 2007 429 436 (Pubitemid 47451426)
19. M.A.M. Ali, W.J. Cho, B. Hudson, Z. Kassiri, H. Granzier, and R. Schulz Titin is a target of MMP-2: implications in myocardial ischemia/reperfusion injury Circulation 122 2010 2039 2047
20. M.L. Coker, M.A. Doscher, C.V. Thomas, Z.S. Galis, and F.G. Spinale Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations Am J Physiol 277 1999 H777 H787 (Pubitemid 29415994)
21. Z.S. Galis, G.K. Sukhova, M.W. Lark, and P. Libby Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques J Clin Invest 94 1994 2493 2503 (Pubitemid 24379627)
22. R. Hanemaaijer, P. Koolwijk, L. le Clercq, W.J. de Vree, and V.W. van Hinsbergh Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells, Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester Biochem J 296 1993 803 809 (Pubitemid 24008200)
23. S. Heymans, A. Luttun, D. Nuyens, G. Theilmeier, E. Creemers, and L. Moons Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure Nat Med 5 1999 1135 1142 (Pubitemid 29474417)
24. M.M. Castro, E. Rizzi, C.M. Prado, M.A. Rossi, J.E. Tanus-Santos, and R.F. Gerlach Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling Matrix Biol 29 2010 194 201
25. J.F. Woessner Jr. Role of matrix proteases in processing enamel proteins Connect Tissue Res 39 1998 69 73
26. H. Nagase, and J.F. Woessner Jr. Matrix metalloproteinases J Biol Chem 274 1999 21491 21494
27. T. Okamoto, T. Akaike, T. Sawa, Y. Miyamoto, A. van der Vliet, and H. Maeda Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation J Biol Chem 276 2001 29596 29602
28. H.E. Van Wart, and H. Birkedal-Hansen The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family Proc Natl Acad Sci USA 87 1990 5578 5582
29. T. Okamoto, T. Akaike, T. Nagano, S. Miyajima, M. Suga, and M. Ando Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide Arch Biochem Biophys 342 1997 261 274 (Pubitemid 27251247)
30. S. Viappiani, A.C. Nicolescu, A. Holt, G. Sawicki, B.D. Crawford, and H. Leon Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione Biochem Pharmacol 77 2009 826 834
31. Q.X. Sang, W.G. Stetler-Stevenson, L.A. Liotta, and S.W. Byers Identification of type IV collagenase in rat testicular cell culture: influence of peritubular-Sertoli cell interactions Biol Reprod 43 1990 956 964
32. M.R. Bergman, S. Cheng, N. Honbo, L. Piacentini, J.S. Karliner, and D.H. Lovett A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers Biochem J 369 2003 485 496 (Pubitemid 36246232)
33. M.A. Alfonso-Jaume, M.R. Bergman, R. Mahimkar, S. Cheng, Z.Q. Jin, and J.S. Karliner Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB Am J Physiol Heart Circ Physiol 291 2006 H1838 H1846 (Pubitemid 44497691)
34. S.J. Lee, S.S. Bae, K.H. Kim, W.S. Lee, B.Y. Rhim, and K.W. Hong High glucose enhances MMP-2 production in adventitial fibroblasts via Akt1-dependent NF-kappaB pathway FEBS Letters 581 2007 4189 4194 (Pubitemid 47301852)
35. S. Lehoux, C.A. Lemarie, B. Esposito, H.R. Lijnen, and A. Tedgui Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling Circulation 109 2004 1041 1047 (Pubitemid 38282859)
36. Y. Ben-Yosef, N. Lahat, S. Shapiro, H. Bitterman, and A. Miller Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation Circ Res 90 2002 784 791 (Pubitemid 34633894)
37. A.M. Deschamps, and F.G. Spinale Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation Cardiovasc Res 69 2006 666 676 (Pubitemid 43139729)
38. S. Philip, and G.C. Kundu Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways J Biol Chem. 278 2003 14487 14497 (Pubitemid 36800002)
39. F.G. Spinale, M.L. Coker, L.J. Heung, B.R. Bond, H.R. Gunasinghe, and T. Etoh A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure Circulation 102 2000 1944 1949
40. D.J. Mountain, M. Singh, B. Menon, and K. Singh Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKC alpha/beta1 and MAPKs Am J Physiol Cell Physiol 292 2007 C867 C875
41. X. Liu, G. Manzano, D.H. Lovett, and H.T. Kim Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional regulation in skeletal muscle atrophy Biochem Biophys Res Commun 396 2010 219 223
42. M. Sariahmetoglu, B.D. Crawford, H. Leon, J. Sawicka, L. Li, and B.J. Ballermann Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation FASEB J 21 2007 2486 2495 (Pubitemid 47230678)
43. Sariahmetoglu M, Skrzypiec M, Youssef N, Sawicka J, Holmes C, Sawicki G, Schulz R. Maintaining matrix metalloproteinase- 2 in its phosphorylated form protects the heart from ischemia/reperfusion injury. J Mol Cell Cardiol (submitted for publication).
44. A.H. Baker, D.R. Edwards, and G. Murphy Metalloproteinase inhibitors: biological actions and therapeutic opportunities J Cell Sci 115 2002 3719 3727 (Pubitemid 35203598)
45. K. Brew, D. Dinakarpandian, and H. Nagase Tissue inhibitors of metalloproteinases: evolution, structure and function Biochim Biophys Acta 7 2000 1 2
46. G.I. Goldberg, A. Strongin, I.E. Collier, L.T. Genrich, and B.L. Marmer Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin J Biol Chem 267 1992 4583 4591
47. G. Castoldi, C.R. di Gioia, C. Travaglini, G. Busca, S. Redaelli, and C. Bombardi Angiotensin II increases tissue-specific inhibitor of metalloproteinase-2 expression in rat aortic smooth muscle cells in vivo: evidence of a pressure-independent effect Clin Exp Pharmacol Physiol 34 2007 205 209 (Pubitemid 46148263)
48. J. Li, P.L. Schwimmbeck, C. Tschope, S. Leschka, L. Husmann, and S. Rutschow Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction Cardiovasc Res 56 2002 235 247 (Pubitemid 35223494)
49. C.C. Chua, R.C. Hamdy, and B.H. Chua Angiotensin II induces TIMP-1 production in rat heart endothelial cells Biochim Biophys Acta 28 1996 175 180
50. G. Castoldi, C.R. Di Gioia, F. Pieruzzi, C. D'Orlando, W.M. Van De Greef, and G. Busca Ang II increases TIMP-1 expression in rat aortic smooth muscle cells in vivo Am J Physiol Heart Circ Physiol 284 2003 H635 H643 (Pubitemid 36142892)
51. N. Pavloff, P.W. Staskus, N.S. Kishnani, and S.P. Hawkes A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the timp family J Biol Chem 267 1992 17321 17326
52. P.W. Fedak, D.S. Smookler, Z. Kassiri, N. Ohno, K.J. Leco, and S. Verma TIMP-3 deficiency leads to dilated cardiomyopathy Circulation 110 2004 2401 2409 (Pubitemid 39407346)
53. J.S. Ikonomidis, J.A. Jones, J.R. Barbour, R.E. Stroud, L.L. Clark, and B.S. Kaplan Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome Circulation 114 2006 I365 I370 (Pubitemid 44297177)
54. K.J. Leco, S.S. Apte, G.T. Taniguchi, S.P. Hawkes, R. Khokha, and G.A. Schultz Murine tissue inhibitor of metalloproteinases-4 (TIMP-4): cDNA isolation and expression in adult mouse tissues FEBS Lett 401 1997 213 217 (Pubitemid 27056118)
55. C.J. Schulze, W. Wang, W.L. Suarez-Pinzon, J. Sawicka, G. Sawicki, and R. Schulz Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury Circulation 107 2003 2487 2492 (Pubitemid 36605233)
56. M.J. Cox, U.A. Hawkins, B.D. Hoit, and S.C. Tyagi Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer Circulation 109 2004 2123 2128 (Pubitemid 38620222)
57. J.T. Peterson Matrix metalloproteinase inhibitor development and the remodeling of drug discovery Heart Fail Rev 9 2004 63 79 (Pubitemid 38202142)
58. A. Yamada, A. Uegaki, T. Nakamura, and K. Ogawa ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs Inflamm Res 49 2000 144 146 (Pubitemid 30262710)
59. E. Koivunen, W. Arap, H. Valtanen, A. Rainisalo, O.P. Medina, and P. Heikkila Tumor targeting with a selective gelatinase inhibitor Nat Biotechnol 17 1999 768 774 (Pubitemid 29365104)
60. S. Higashi, and K. Miyazaki Identification of a region of beta-amyloid precursor protein essential for its gelatinase A inhibitory activity J Biol Chem 278 2003 14020 14028 (Pubitemid 36799946)
61. L.M. Golub, H.M. Lee, G. Lehrer, A. Nemiroff, T.F. McNamara, and R. Kaplan Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action J Periodontal Res 18 1983 516 526 (Pubitemid 14221747)
62. L.M. Golub, N. Ramamurthy, T.F. McNamara, B. Gomes, M. Wolff, and A. Casino Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease J Periodontal Res 19 1984 651 655 (Pubitemid 15168777)
63. L.M. Golub, H.M. Lee, M.E. Ryan, W.V. Giannobile, J. Payne, and T. Sorsa Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms Adv Dent Res 12 1998 12 26
64. H.M. Lee, S.G. Ciancio, G. Tuter, M.E. Ryan, E. Komaroff, and L.M. Golub Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug J Periodontol 75 2004 453 463 (Pubitemid 38461128)
65. A.K. Chow, J. Cena, and R. Schulz Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature Br J Pharmacol 152 2007 189 205 (Pubitemid 47517601)
66. F.J. Villarreal, M. Griffin, J. Omens, W. Dillmann, J. Nguyen, and J. Covell Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling Circulation 108 2003 1487 1492 (Pubitemid 37176456)
67. N. Yaras, M. Sariahmetoglu, A. Bilginoglu, A. Aydemir-Koksoy, A. Onay-Besikci, and B. Turan Protective action of doxycycline against diabetic cardiomyopathy in rats Br J Pharmacol 155 2008 1174 1184
68. V.W. Yong, J. Wells, F. Giuliani, S. Casha, C. Power, and L.M. Metz The promise of minocycline in neurology Lancet Neurol. 3 2004 744 751 (Pubitemid 39535260)
69. L.M. Golub, T.F. McNamara, G. D'Angelo, R.A. Greenwald, and N.S. Ramamurthy A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity J Dent Res 66 1987 1310 1314 (Pubitemid 17127109)
70. D.E. Carney, U.G. McCann, H.J. Schiller, L.A. Gatto, J. Steinberg, and A.L. Picone Metalloproteinase inhibition prevents acute respiratory distress syndrome J Surg Res 99 2001 245 252 (Pubitemid 32703443)
71. S.R. Maitra, S. Bhaduri, P.D. Valane, T. Tervahartiala, T. Sorsa, and N. Ramamurthy Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis Shock 20 2003 280 285
72. J. Steinberg, J. Halter, H. Schiller, L. Gatto, D. Carney, and H.M. Lee Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model Shock 24 2005 348 356 (Pubitemid 41416521)
73. J. Steinberg, J. Halter, H.J. Schiller, M. Dasilva, S. Landas, and L.A. Gatto Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats J Surg Res 111 2003 185 195 (Pubitemid 36808908)
74. T. Salo, Y. Soini, J. Oiva, Kariylitalo, A. Nissinen, and F. Biancari Chemically modified tetracyclines (CMT-3 and CMT-8) enable control of the pathologic remodellation of human aortic valve stenosis via MMP-9 and VEGF inhibition Int J Cardiol 111 2006 358 364 (Pubitemid 44205290)
75. L.M. Golub, N.S. Ramamurthy, T.F. McNamara, R.A. Greenwald, and B.R. Rifkin Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs Crit Rev Oral Biol Med 2 1991 297 321
76. L.H. Nip, V.J. Uitto, and L.M. Golub Inhibition of epithelial cell matrix metalloproteinases by tetracyclines J Periodontal Res 28 1993 379 385 (Pubitemid 23282035)
77. C. Richards, L. Pantanowitz, and B.J. Dezube Antimicrobial and non-antimicrobial tetracyclines in human cancer trials Pharmacol Res 63 2011 151 156
78. A. Page-McCaw, A.J. Ewald, and Z. Werb Matrix metalloproteinases and the regulation of tissue remodelling Nat Rev Mol Cell Biol 8 2007 221 233
79. W. Cai, R. Vosschulte, A. Afsah-Hedjri, S. Koltai, E. Kocsis, and D. Scholz Altered balance between extracellular proteolysis and antiproteolysis is associated with adaptive coronary arteriogenesis J Mol Cell Cardiol 32 2000 997 1011 (Pubitemid 30663107)
80. K.K. Linask, S. Manisastry, and M. Han Cross talk between cell-cell and cell-matrix adhesion signaling pathways during heart organogenesis: implications for cardiac birth defects Microsc Microanal 11 2005 200 208 (Pubitemid 40870188)
81. K.K. Linask, M. Han, D.H. Cai, P.R. Brauer, and S.M. Maisastry Cardiac morphogenesis: matrix metalloproteinase coordination of cellular mechanisms underlying heart tube formation and directionality of looping Dev Dyn 233 2005 739 753 (Pubitemid 40853450)
82. A. Ratajska, and J.P. Cleutjens Embryogenesis of the rat heart: the expression of collagenases Basic Res Cardiol 97 2002 189 197 (Pubitemid 34464152)
83. T. Kato, T. Kure, J.H. Chang, E.E. Gabison, T. Itoh, and S. Itohara Diminished corneal angiogenesis in gelatinase A-deficient mice FEBS Lett 508 2001 187 190 (Pubitemid 33079244)
84. J. Oh, R. Takahashi, E. Adachi, S. Kondo, S. Kuratomi, and A. Noma Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice Oncogene 23 2004 5041 5048 (Pubitemid 38938737)
85. + exchanger regulation for cardiac protection: a RSKy approach? Curr Opin Pharmacol 8 2008 133 140
86. I. Andreadou, E.K. Iliodromitis, M. Koufaki, and D.T. Kremastinos Pharmacological pre- and post- conditioning agents: reperfusion-injury of the heart revisited Mini Rev Med Chem 8 2008 952 959
87. B. Ostadal The past, the present and the future of experimental research on myocardial ischemia and protection Pharmacol Rep 61 2009 3 12
88. W. Yasmin, K.D. Strynadka, and R. Schulz Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts Cardiovasc Res 33 1997 422 432 (Pubitemid 27072648)
89. E.R. Frears, Z. Zhang, D.R. Blake, J.P. O'Connell, and P.G. Winyard Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite FEBS Lett 381 1996 21 24 (Pubitemid 26070416)
90. S. Donnini, M. Monti, R. Roncone, L. Morbidelli, M. Rocchigiani, and S. Oliviero Peroxynitrite inactivates human-tissue inhibitor of metalloproteinase-4 FEBS Lett 582 2008 1135 1140
91. M. Donato, V. D'Annunzio, B. Buchholz, V. Miksztowicz, C.L. Carrion, and L.B. Valdez Role of matrix metalloproteinase-2 in the cardioprotective effect of ischaemic postconditioning Exp Physiol 95 2010 274 281
92. J. Fert-Bober, H. Leon, J. Sawicka, R.S. Basran, R.M. Devon, and R. Schulz Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion Basic Res Cardiol 103 2008 431 443
93. H. Leon, I. Baczko, G. Sawicki, P.E. Light, and R. Schulz Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte Brit J Pharmacol 153 2008 676 683 (Pubitemid 351271762)
94. W. Wang, G. Sawicki, and R. Schulz Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2 Cardiovasc Res 53 2002 165 174 (Pubitemid 34020777)
95. J. Chen, C.H. Tung, J.R. Allport, S. Chen, R. Weissleder, and P.L. Huang Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction Circulation 111 2005 1800 1805 (Pubitemid 40525145)
96. M.O. Griffin, M. Jinno, L.A. Miles, and F.J. Villarreal Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition Mol Cell Biochem 270 2005 1 11 (Pubitemid 40425232)
97. M.M. Lalu, E. Pasini, C.J. Schulze, M. Ferrari-Vivaldi, G. Ferrari-Vivaldi, and T. Bachetti Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart Eur Heart J 26 2005 27 35 (Pubitemid 40221120)
98. F.G. Spinale, C.N. Koval, A.M. Deschamps, R.E. Stroud, and J.S. Ikonomidis Dynamic changes in matrix metalloprotienase activity within the human myocardial interstitium during myocardial arrest and reperfusion Circulation 118 2008 S16 S23
99. A. Sokal, M. Zembala, A. Radomski, A. Kocher, J. Pacholewicz, and J. Los A differential release of matrix metalloproteinases 9 and 2 during coronary artery bypass grafting and off-pump coronary artery bypass surgery J Thorac Cardiovasc Surg 137 2009 1218 1224
100. University of Alberta Protection of the heart with doxycycline during coronary artery bypass grafting In: clinicaltrialsgov 2000-2009 National Library of Medicine Bethesda MD, USA Available at: http://clinicaltrials.gov/ showNCT00246740
101. D.L. Brown, K.K. Desai, B.A. Vakili, C. Nouneh, H.M. Lee, and L.M. Golub Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial Arterioscler Thromb Vasc Biol 24 2004 733 738 (Pubitemid 38451612)
102. P. Libby, and P.M. Ridker Inflammation and atherosclerosis: role of C-reactive protein in risk assessment Am J Med 116 2004 9S 16S
103. G. Tuter, B. Kurtis, M. Serdar, T. Aykan, K. Okyay, and A. Yucel Effects of scaling and root planing and sub-antimicrobial dose doxycycline on oral and systemic biomarkers of disease in patients with both chronic periodontitis and coronary artery disease J Clin Periodontol 34 2007 673 681
104. S. Blankenberg, H.J. Rupprecht, O. Poirier, C. Bickel, M. Smieja, and G. Hafner Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease Circulation 107 2003 1579 1585 (Pubitemid 36397324)
105. M.P. Hudson, P.W. Armstrong, W. Ruzyllo, J. Brum, L. Cusmano, and P. Krzeski Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial J Am Coll Cardiol 48 2006 15 20 (Pubitemid 43929218)
106. A.C. Lau, T.T. Duong, S. Ito, G.J. Wilson, and R.S. Yeung Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease Clin Exp Immunol 157 2009 300 309
107. F.R. Gutierrez, M.M. Lalu, F.S. Mariano, C.M. Milanezi, J. Cena, and R.F. Gerlach Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection J Infect Dis 197 2008 1468 1476 (Pubitemid 351706471)
108. M.M. Lalu, C.Q. Gao, and R. Schulz Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9 Mol Cell Biochem 251 2003 61 66 (Pubitemid 37220710)
109. P.J. Gavin, S.E. Crawford, S.T. Shulman, F.L. Garcia, and A.H. Rowley Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease Arterioscler Thromb Vasc Biol 23 2003 576 581 (Pubitemid 36438068)
110. P.K. Chua, M.E. Melish, Q. Yu, R. Yanagihara, K.S. Yamamoto, and V.R. Nerurkar Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease Clin Diagn Lab Immunol 10 2003 308 314 (Pubitemid 36314457)
111. D.Y. Leung, R.S. Cotran, E. Kurt-Jones, J.C. Burns, J.W. Newburger, and J.S. Pober Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease Lancet 2 1989 1298 1302 (Pubitemid 20005671)
112. M.M. Lalu, T. Csont, and R. Schulz Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia Crit Care Med 32 2004 1332 1337 (Pubitemid 38738589)
113. A. Rassi Jr., A. Rassi, and J.A. Marin-Neto Chagas disease Lancet 375 2010 1388 1402
114. M.M. Teixeira, R.T. Gazzinelli, and J.S. Silva Chemokines, inflammation and Trypanosoma cruzi infection Trends Parasitol 18 2002 262 265 (Pubitemid 34569236)
115. C. Cheung, H. Luo, B. Yanagawa, H.S. Leong, D. Samarasekera, and J.C. Lai Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis Cardiovasc Pathol 15 2006 66 74
116. C. Cheung, D. Marchant, E.K. Walker, Z. Luo, J. Zhang, and B. Yanagawa Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice Circulation 117 2008 1574 1582 (Pubitemid 351440645)
117. J.D. Raffetto, and R.A. Khalil Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease Biochem Pharmacol 75 2008 346 359 (Pubitemid 350298459)
118. A.C. Newby Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates Cardiovasc Res 69 2006 614 624 (Pubitemid 43140745)
119. A.C. Newby Dual role of matrix metalloproteinases (MATRIXINS) in intimal thickening and atherosclerotic plaque rupture Physiol Rev 85 2005 1 31 (Pubitemid 40171256)
120. Yasmin, C.M. McEniery, S. Wallace, Z. Dakham, P. Pulsalkar, and K. Maki-Petaja Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness Arterioscl Thromb Vas 25 2005 372 378 (Pubitemid 40189160)
121. C. Bouvet, L.A. Gilbert, D. Girardot, D. deBlois, and P. Moreau Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition Hypertension 45 2005 432 437 (Pubitemid 40315814)
122. M. Flamant, S. Placier, C. Dubroca, B. Esposito, I. Lopes, and C. Chatziantoniou Role of matrix metalloproteinases in early hypertensive vascular remodeling Hypertension 50 2007 212 218 (Pubitemid 46986043)
123. A.C. Newby Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability Arterioscler Thromb Vasc Biol 28 2008 2108 2114
124. G.M. Longo, W. Xiong, T.C. Greiner, Y. Zhao, N. Fiotti, and B.T. Baxter Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms J Clin Invest 110 2002 625 632 (Pubitemid 34988786)
125. A.W. Chung, H.H. Yang, M.W. Radomski, and C. van Breemen Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9 Circ Res 102 2008 e73 e85 (Pubitemid 351591557)
126. H. Yang, J. Kim, E. Chum, C. van Breemen, and A. Chung Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome J Thorac Cardiovasc Surg 140 2010 305 312
127. C.A. Lemarie, P.L. Tharaux, and S. Lehoux Extracellular matrix alterations in hypertensive vascular remodeling J Mol Cell Cardiol 48 2009 433 439
128. I. Vanlaere, and C. Libert Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock Clin Microbiol Rev 22 2009 224 239
129. C. Fernandez-Patron, M.W. Radomski, and S.T. Davidge Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor Circ Res 85 1999 906 911 (Pubitemid 29534165)
130. C. Fernandez-Patron, K.G. Stewart, Y. Zhang, E. Koivunen, M.W. Radomski, and S.T. Davidge Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction Circ Res 87 2000 670 676
131. A. Martinez, H.R. Oh, E.J. Unsworth, C. Bregonzio, J.M. Saavedra, and W.G. Stetler-Stevenson Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator Biochem J 383 2004 413 418 (Pubitemid 39546110)
132. L. Hao, T. Nishimura, H. Wo, and C. Fernandez-Patron Vascular responses to alpha1-adrenergic receptors in small rat mesenteric arteries depend on mitochondrial reactive oxygen species Arterioscler Thromb Vasc Biol 26 2006 819 825 (Pubitemid 43732157)
133. D.K. Chew, M.S. Conte, and R.A. Khalil Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction J Vasc Surg 40 2004 1001 1010 (Pubitemid 39535233)
134. K.R. Waitkus-Edwards, L.A. Martinez-Lemus, X. Wu, J.P. Trzeciakowski, M.J. Davis, and G.E. Davis Alpha(4)beta(1) integrin activation of L-type calcium channels in vascular smooth muscle causes arteriole vasoconstriction Circ Res 90 2002 473 480 (Pubitemid 34633918)
135. G. D'Angelo, J.E. Mogford, G.E. Davis, M.J. Davis, and G.A. Meininger Integrin-mediated reduction in vascular smooth muscle [Ca2+]i induced by RGD-containing peptide Am J Physiol 272 1997 H2065 H2070
136. S.R. Macfarlane, M.J. Seatter, T. Kanke, G.D. Hunter, and R. Plevin Proteinase-activated receptors Pharmacol Rev 53 2001 245 282 (Pubitemid 32476117)
137. W.C. Parks, C.L. Wilson, and Y.S. Lopez-Boado Matrix metalloproteinases as modulators of inflammation and innate immunity Nat Rev Immunol 4 2004 617 629 (Pubitemid 39025047)
138. J. Hu, P.E. Van den Steen, Q.X. Sang, and G. Opdenakker Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases Nat Rev Drug Discov 6 2007 480 498 (Pubitemid 47064570)
139. A. Kumar, C. Haery, and J.E. Parrillo Myocardial dysfunction in septic shock: Part I Clinical manifestation of cardiovascular dysfunction. J Cardiothorac Vasc Anesth 15 2001 364 376
140. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M.R. Pinsky Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit Care Med 29 2001 1303 1310 (Pubitemid 32641789)
141. S.R. Crowley The pathogenesis of septic shock Heart Lung 25 1996 124 134 (Pubitemid 26135204)
142. N. Matsuda, and Y. Hattori Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction J Smooth Muscle Res 43 2007 117 137
143. D.D. Rees, S. Cellek, R.M. Palmer, and S. Moncada Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock Biochem Biophys Res Commun 173 1990 541 547
144. R. Schulz, E. Nava, and S. Moncada Induction and potential biological relevance of a Ca2+ -independent nitric oxide synthase in the myocardium Br J Pharmacol 105 1992 575 580
145. G.J. Hom, S.K. Grant, G. Wolfe, T.J. Bach, D.E. MacIntyre, and N.I. Hutchinson Lipopolysaccharide-induced hypotension and vascular hyporeactivity in the rat: tissue analysis of nitric oxide synthase mRNA and protein expression in the presence and absence of dexamethasone, NG-monomethyl-L-arginine or indomethacin J Pharmacol Exp Ther 272 1995 452 459
146. R. Schulz, D.L. Panas, R. Catena, S. Moncada, P.M. Olley, and G.D. Lopaschuk The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha Br J Pharmacol 114 1995 27 34
147. Y. Gui, X.L. Zheng, M.D. Hollenberg, and Interleukin-1beta Src- and non-Src tyrosine kinases, and nitric oxide synthase induction in rat aorta in vitro Am J Physiol Heart Circ Physiol 279 2000 H566 H576
148. R. Hernanz, M.J. Alonso, H. Zibrandtsen, Y. Alvarez, M. Salaices, and U. Simonsen Measurements of nitric oxide concentration and hyporeactivity in rat superior mesenteric artery exposed to endotoxin Cardiovasc Res 62 2004 202 211 (Pubitemid 38326826)
149. P. Pickkers, M.J. Dorresteijn, M.P. Bouw, J.G. van der Hoeven, and P. Smits In vivo evidence for nitric oxide-mediated calcium-activated potassium-channel activation during human endotoxemia Circulation 114 2006 414 421 (Pubitemid 44264823)
150. S. Cuzzocrea, E. Mazzon, R. Di Paola, E. Esposito, H. Macarthur, and G.M. Matuschak A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin-induced shock J Pharmacol Exp Ther 319 2006 73 81 (Pubitemid 44455112)
151. C. Szabo, A.L. Salzman, and H. Ischiropoulos Endotoxin triggers the expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in the rat aorta in vivo FEBS Lett 363 1995 235 238
152. L.M. Golub, S. Ciancio, N.S. Ramamamurthy, M. Leung, and T.F. McNamara Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans J Periodontal Res 25 1990 321 330
153. M.M. Lalu, J. Cena, R. Chowdhury, A. Lam, and R. Schulz Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction Br J Pharmacol 149 2006 31 42 (Pubitemid 44299066)
154. J.J. Cena, M.M. Lalu, W.J. Cho, A.K. Chow, M.L. Bagdan, and E.E. Daniel Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia Am J Physiol Heart Circ Physiol 298 2009 H45 H51
155. J. Albert, A. Radomski, A. Soop, A. Sollevi, C. Frostell, and M.W. Radomski Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers Acta Anaesthesiol Scand 47 2003 407 410 (Pubitemid 36438854)
156. U. Hoffmann, T. Bertsch, E. Dvortsak, C. Liebetrau, S. Lang, and V. Liebe Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis Scand J Infect Dis 38 2006 867 872 (Pubitemid 44489515)
157. L. Lorente, M.M. Martin, L. Labarta, C. Diaz, J. Sole-Violan, and J. Blanquer Matrix metalloproteinase-9-10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis Crit Care 13 2009 R158 R166
158. D.G. Hesse, K.J. Tracey, Y. Fong, K.R. Manogue, M.A. Palladino Jr., and A. Cerami Cytokine appearance in human endotoxemia and primate bacteremia Surg Gynecol Obstet 166 1988 147 153
159. S. Okusawa, J.A. Gelfand, T. Ikejima, R.J. Connolly, and C.A. Dinarello Interleukin 1 induces a shock-like state in rabbits, Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition J Clin Invest 81 1988 1162 1172
160. J. Cena, M.M. Lalu, C. Rosenfelt, and R. Schulz Endothelial dependence of matrix metalloproteinase-mediated vascular hyporeactivity caused by lipopolysaccharide Eur J Pharmacol 582 2008 116 122
161. J. Hu, P.E. Van den Steen, C. Dillen, and G. Opdenakker Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock Biochem Pharmacol 70 2005 535 544 (Pubitemid 40978543)
162. B. Dubois, S. Starckx, A. Pagenstecher, J. Oord, B. Arnold, G. Opdenakker, and Gelatinase B deficiency protects against endotoxin shock Eur J Immunol 32 2002 2163 2171 (Pubitemid 34965879)
163. M.M. Castro, J.J. Cena, M.P. Walsh, and R. Schulz Matrix metalloproteinse-2 may cleave calponin in vascular smooth muscle during endotoxemia Cardiovasc Res 87 2010 S99 [abstract].
164. J.M. Halter, L.A. Pavone, J.M. Steinberg, L.A. Gatto, J. DiRocco, and S. Landas Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24 hours after cecal ligation and puncture Shock 26 2006 587 591 (Pubitemid 44789633)
165. S.R. Maitra, M.J. Shapiro, S. Bhaduri, and M.R. El-Maghrabi Effect of chemically modified tetracycline on transforming growth factor-beta1 and caspase-3 activation in liver of septic rats Crit Care Med 33 2005 1577 1581 (Pubitemid 40980615)